Tin tức & Cập nhật

In the final overall survival (OS) analysis of the phase III PAOLA-1*/ENGOT-ov25 trial, the addition of olaparib to bevacizumab provided a survival benefit for women with newly diagnosed advanced ovarian cancer with HRD**-positive (HRD+) tumours.

In low- and middle-income countries (LMICs), there appears to be a long interval between the first onset of breast cancer symptoms and presentation to a healthcare provider, reports a recent study.

Human papillomavirus (HPV) self-sampling for cervical cancer screening is highly acceptable among Singaporean women, with the strategy deemed accurate and easy to perform, a study has found.

The first-in-class KRAS^G12C inhibitor sotorasib significantly improved progression-free survival (PFS) in patients with previously treated non-small cell lung cancer (NSCLC) with KRAS^G12C mutations, according to results of the phase III CodeBreaK 200 trial presented at ESMO 2022.

In cancer patients, the presence of diabetes appears to aggravate the likelihood of developing a secondary malignancy or death, reports a recent Japan study.

Prophylactic granulocyte-colony stimulating factor (G-CSF) results in a significant decrease both in the rate of febrile neutropaenia (FN) and duration of hospitalization for FN in breast cancer patients treated with docetaxel-based chemotherapy regimens (DBRs), according to a recent study.

Treatment with the combination of palbociclib plus bazedoxifene demonstrates clinical efficacy while having an acceptable safety profile in treatment-experienced patients with hormone receptor–positive/HER2-negative (HR+/HER2−) advanced breast cancer, according to the results of a phase Ib/II study.

First-line (1L) acalabrutinib in combination with lenalidomide and rituximab (ALR) has demonstrated high rates of minimal residual disease (MRD)–negative complete remission (CR) in patients with mantle cell lymphoma (MCL), including patients with TP53 mutations, in a single-arm phase II trial reported at the 64^th American Society of Hematology (ASH) Annual Meeting and Exposition.